New Hair Loss Drugs in 2026 and What They Mean for Your Hair

The most important new hair loss drugs of 2026 are clascoterone 5% solution, an extended-release oral minoxidil called VDPHL01, the stem cell activator PP405 and, for alopecia areata (the autoimmune condition that causes patchy hair loss), an immune-calming tablet called upadacitinib. For almost three decades, people with androgenetic alopecia had only topical minoxidil and oral finasteride, which a 2025 review still describes as the only widely approved options (Chen et al., 2025, Drug Des Devel Ther). In the past year, three large late-stage trials in men reported positive results, a stem cell drug entered a phase 2/3 trial and a fourth JAK inhibitor was approved for alopecia areata.

This guide explains how each drug works, what the trials showed and when it could reach patients. Several headline results still come from company announcements rather than peer-reviewed journals, so we state which kind of evidence stands behind each claim.

Why Are New Hair Loss Drugs Appearing Now?

New drugs are appearing because researchers now target the hair follicle from several angles instead of only lowering DHT. In androgenetic alopecia, DHT acts on androgen receptors in genetically sensitive follicles and gradually shrinks the hair, a process called miniaturization. The newer candidates block that receptor directly in the scalp, deliver minoxidil more steadily, or try to restart dormant follicle stem cells, an idea backed by laboratory work on the metabolic switch these cells need to wake up (Flores et al., 2017, Nature Cell Biology). Alopecia areata, an autoimmune form of hair loss unrelated to DHT, has its own new drugs in the JAK inhibitors.

Where Do Finasteride and Minoxidil Stand Today?

Finasteride and minoxidil remain the standard of care, and newer versions of both are already in use.

Oral Finasteride and Dutasteride

Oral finasteride 1 mg is still the main hormonal treatment for men, and dutasteride 0.5 mg produced the largest gain in total hair count at 24 weeks in a network meta-analysis of 23 studies (Gupta et al., 2022, JAMA Dermatology). Our guide to finasteride and minoxidil side effects explains what to expect when starting treatment.

Topical Finasteride

Topical finasteride spray regrows hair with far less of the drug reaching the bloodstream. In a 458-patient phase 3 trial, it added 20.2 hairs versus 6.7 with placebo over 24 weeks, numerically similar to the oral finasteride arm of the same trial, although the study was not designed to compare the two head to head, and peak blood levels were more than 100 times lower than with the tablet (Piraccini et al., 2022, Journal of the European Academy of Dermatology and Venereology).

Low-Dose Oral Minoxidil

Low-dose oral minoxidil is now one of the most prescribed off-label hair treatments. In a safety study of 1,404 patients, the most common side effect was unwanted body hair (15.1%), and only 1.7% stopped because of side effects (Vañó-Galván et al., 2021, Journal of the American Academy of Dermatology). It is not always better than the topical form, since a 24-week trial in 90 men found no significant overall advantage for 5 mg tablets over 5% solution (Penha et al., 2024, JAMA Dermatology).

Clascoterone 5% Solution, a Topical Androgen Receptor Blocker

Clascoterone is the new hair loss drug closest to approval in the US and Europe. It occupies the androgen receptor inside the follicle so DHT cannot deliver its miniaturizing signal, and because it breaks down quickly in the bloodstream it aims to avoid body-wide hormonal effects. The same molecule is already approved as a 1% acne cream, so regulators hold years of skin safety data on it.

The SCALP 1 and SCALP 2 phase 3 trials (NCT05910450, NCT05914805) enrolled 1,465 men, according to the developer. Topline results reported by the Dermatology Education Foundation showed hair count rising 539% and 168% more than vehicle in the two trials, although absolute hair gains, not yet published in full, will matter more. As reported by Dermatology Times, men who stayed on treatment for 12 months gained 2.39 times more hair than those switched to vehicle, with safety comparable to vehicle. The US application is planned for early 2027, which points to a launch between late 2027 and 2028.

VDPHL01, an Investigational Oral Minoxidil for Hair Loss

VDPHL01 is an extended-release minoxidil tablet developed specifically for hair loss, and it is still investigational, which means it is not yet approved in any country. According to the developer, it avoids the sharp blood peaks of standard minoxidil that are linked to a racing heart and fluid retention, while keeping levels above the threshold needed for hair growth for longer.

VDPHL01 has now passed two placebo-controlled trials in men. In Study 302, the once-daily dose added 30.3 hairs per square centimeter at six months against 7.3 with placebo, as reported by Quartz. The confirmatory Study 304, announced on 19 October 2026, showed gains of 28.6 hairs once daily and 36.4 twice daily against 6.6 with placebo in 536 men, with no treatment-related serious or cardiac adverse events of special interest. Both results are company-reported, no filing date has been given yet, and approval in 2027 or 2028 remains the realistic window. A placebo-controlled trial in women is due in the first half of 2027, and our guide to hair loss in women covers the options available today.

Pyrilutamide and GT20029, Androgen Receptor Drugs From China

Pyrilutamide and GT20029 are two androgen receptor drugs from the same Chinese developer, and their first approval is expected in China. As reported by BioWorld, topical pyrilutamide (KX-826) met its primary endpoint in a 52-week phase 3 trial in Chinese men in March 2026, adding 15.33 hairs per square centimeter versus 4.68 with placebo. These results are not yet peer reviewed, and cosmetic products sold online under the KX-826 name are not regulated medicines.

GT20029 belongs to a class called PROTACs, which mark the androgen receptor for destruction instead of blocking it. In a peer-reviewed phase 2 trial of 180 Chinese men, both its once-daily and twice-weekly regimens beat placebo after 12 weeks with no drug-related serious adverse events (Hu et al., 2025, Journal of Dermatological Treatment).

PP405 and ET-02, Drugs That Target Dormant Follicle Stem Cells

PP405 and ET-02 try to restart follicles that have stopped producing hair, which no approved drug does.

What Did the PP405 Trial Show?

In a phase 2a study of 78 adults, as reported by Dermatology Times, four weeks of a 0.05% gel led 31% of men with more advanced hair loss to a hair density increase above 20% at week eight, against 0% on placebo. The study was small and the 31% applies to a subgroup. The phase 2/3 AWAKEN trial (NCT07819435) began in September 2026 and is recruiting about 600 men with Norwood Type IV or V hair loss for 24 weeks of treatment, with main results expected around the end of 2027.

How Far Along Is ET-02?

ET-02 is at a much earlier stage. According to Clinical Trials Arena, its first study in 24 men reported six times more hair growth than placebo after four weeks, and a six-month phase 2 trial is expected to start in 2027.

Which Earlier-Stage Hair Loss Drugs Are Worth Watching?

Three earlier-stage candidates use mechanisms none of the leading drugs share. HMI-115 is an injectable antibody against the prolactin receptor, and in an open-label phase 1b study men gained an average of 14 hairs per square centimeter. ABS-201 targets the same receptor and is tested for hair growth as repeated injections under the skin (NCT07317544), after interim single-dose data in 32 volunteers showed no serious adverse events and a half-life of at least 65 days. TDM-105795 is a topical thyroid hormone mimetic whose phase 2a trial reported gains of 20 to 24 hairs without a clean placebo comparison.

JAK Inhibitors Have Changed Alopecia Areata Treatment

JAK inhibitors are oral drugs that interrupt the immune attack on hair follicles in alopecia areata, and they are now the first effective systemic treatment for severe cases. The table shows the share of patients regaining at least 80% scalp coverage (a SALT score of 20 or less) in the pivotal trials.

Upadacitinib is the key development of 2026, and as reported by HCPLive, up to 37% of patients regained complete scalp coverage by week 52. JAK inhibitors need specialist monitoring for infections, blood clots and cardiovascular events.

People with alopecia areata who are considering a hair transplant should wait until the condition has been stable for a long period, because an active immune attack can affect transplanted follicles too. Our surgeons review this history before planning any procedure, so mention any past patchy hair loss at your first consultation and we will advise whether surgery, medication or both is the safer route.

Every New Hair Loss Drug Compared

This table summarizes where each candidate stood on 20 October 2026 and what kind of evidence supports it.

Why Buying Unapproved Hair Loss Drugs Online Is Risky

Unapproved hair loss drugs sold online are risky because the buyer cannot verify what is in the bottle. Products using names such as PP405 or pyrilutamide may contain the wrong molecule, the wrong strength or contaminants, and a drug tested in a specific gel may do nothing, or cause harm, in a homemade solution. Anyone determined to try an investigational drug should look for a supervised trial on ClinicalTrials.gov.

Will New Medications Replace Hair Transplant Surgery?

New medications are very unlikely to replace hair transplant surgery for people with established baldness. Every drug in this guide works on follicles that still exist, and even PP405 targets follicles that are dormant rather than gone. Where years of hair loss have left smooth scalp with no follicles left, moving healthy, DHT-resistant follicles from the back of the head remains the only reliable way to restore density. Medication and surgery work as partners, with drugs protecting the native hair around a transplant, as our article on using minoxidil and finasteride after a hair transplant explains.

“Every new drug that reaches patients is good news for us as surgeons, because a stable scalp lets us plan a transplant that still looks natural twenty years later. What no medicine can do is bring back a follicle that has already disappeared. For those areas, surgery restores and medication protects.” Dr. Gökay Bilgin, co-founder of Smile Hair Clinic.

For hair loss that medication can no longer reverse, a hair transplant in Turkey remains the most established long-term solution. At Smile Hair Clinic, the first and only hair transplant clinic worldwide to hold the TEMOS A-Rated Certificate, surgeons use Sapphire FUE and DHI and build a medication plan around each surgery. Send us photos of your hair for a personal assessment, and see the hair transplant cost in Turkey page for what each all-inclusive package includes.

FAQ

When will clascoterone be available for hair loss?

A US launch between late 2027 and 2028 is the most realistic estimate. The clascoterone acne cream sold today is a different, lower-strength product and should not be used on the scalp.

Is oral minoxidil safe for hair loss?

Yes, for most people when prescribed and monitored by a doctor, with unwanted body hair as the most common side effect. It is not suitable for some people with heart conditions or low blood pressure.

Is topical finasteride safer than oral finasteride?

Approved topical sprays expose the body to far less of the drug than tablets while producing a similar hair gain in trials. Which form suits you best is a decision to make with your doctor.

Can women use the new hair loss drugs?

Some of them. VDPHL01 has early data in women with a placebo-controlled trial due in 2027, while clascoterone was tested in men only, and anti-androgens need particular care in women who could become pregnant.

Do JAK inhibitors work for male pattern baldness?

No. JAK inhibitors are approved for alopecia areata, an autoimmune condition, and have no proven role in androgenetic alopecia.

Will PP405 regrow hair on a completely bald scalp?

Probably not. Its early trial showed new hair from follicles that were present but inactive, and no drug is known to recreate follicles that have disappeared.

Should I wait for new drugs instead of getting a hair transplant?

Only if your thinning is early and your follicles are still present, in which case starting proven medication now keeps more follicles for future drugs to work on. Established bald areas are unlikely to respond to new drugs, and a surgeon can clarify your options.

Can I use the new drugs after a hair transplant?

Yes, once approved, drugs such as clascoterone or VDPHL01 would likely protect the native hair around grafts the way finasteride and minoxidil do today. Your surgeon will advise when to start after the scalp has healed.

Sources

Chen S, Li L, Ding W, Zhu Y, Zhou N. Androgenetic alopecia, an update on pathogenesis and pharmacological treatment. Drug Des Devel Ther. 2025;19,7349-7363. doi 10.2147/DDDT.S542000. PubMed

Flores A, Schell J, Krall AS, et al. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nat Cell Biol. 2017;19(9),1017-1026. doi 10.1038/ncb3575. PubMed

Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-α reductase inhibitors in androgenetic alopecia treatment of male patients, a network meta-analysis. JAMA Dermatol. 2022;158(3),266-274. doi 10.1001/jamadermatol.2021.5743. PubMed

Hu R, Wei A, Wu L, et al. Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia, a multicenter, randomized, double-blind, placebo-controlled phase 2 study. J Dermatolog Treat. 2025;36(1),2574304. doi 10.1080/09546634.2025.2574304. PubMed

King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18),1687-1699. doi 10.1056/NEJMoa2110343. PubMed

King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata, a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387),1518-1529. doi 10.1016/S0140-6736(23)00222-2. PubMed

King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata, results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5),880-888. doi 10.1016/j.jaad.2024.06.097. PubMed

Mostaghimi A, Gooderham MJ, Lynde C, et al. Upadacitinib for severe alopecia areata in adults and adolescents, two phase 3 UP-AA randomized clinical trials. JAMA Dermatol. 2026. doi 10.1001/jamadermatol.2026.2853. PubMed

Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia, a randomized clinical trial. JAMA Dermatol. 2024;160(6),600-605. doi 10.1001/jamadermatol.2024.0284. PubMed

Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia, a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2),286-294. doi 10.1111/jdv.17738. PubMed

Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss, a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6),1644-1651. doi 10.1016/j.jaad.2021.02.054. PubMed

US National Library of Medicine. SCALP1 clascoterone solution in male androgenetic alopecia. NCT05910450

US National Library of Medicine. SCALP2 clascoterone solution in male androgenetic alopecia. NCT05914805

US National Library of Medicine. AWAKEN phase 2/3 study of PP405 in adult males. NCT07819435

US National Library of Medicine. HMI-115 phase 2 study in male androgenetic alopecia. NCT06118866

US National Library of Medicine. ABS-201 phase 1/2a HEADLINE study. NCT07317544

US National Library of Medicine. TDM-105795 phase 2 study in male androgenetic alopecia. NCT05802173